The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Zoledronic Acid and Clinical Fractures and Mortality after Hip Fracture
Open accessAbstract
BACKGROUND: Mortality is increased after a hip fracture, and strategies that improve outcomes are needed. METHODS: In this randomized, double-blind, placebo-controlled trial, 1065 patients were assigned to receive yearly intravenous zoledronic acid (at a dose of 5 mg), and 1062 patients were assigned to receive placebo. The infusions were first administered within 90 days after surgical repair of a hip fracture. All patients (mean age, 74.5 years) received supplemental vitamin D and calcium. The median follow-up was 1.9 years. The primary end point was a new clinical fracture. RESULTS: The rates of any new clinical fracture were 8.6% in the zoledronic acid group and 13.9% in the placebo group, a 35% risk reduction with zoledronic acid (P=0.001); the respective rates of a new clinical vertebral fracture were 1.7% and 3.8% (P=0.02), and the respective rates of new nonvertebral fractures were 7.6% and 10.7% (P=0.03). In the safety analysis, 101 of 1054 patients in the zoledronic acid group (9.6%) and 141 of 1057 patients in the placebo group (13.3%) died, a reduction of 28% in deaths from any cause in the zoledronic acid group (P=0.01). The most frequent adverse events in patients receiving zoledronic acid were pyrexia, myalgia, and bone and musculoskeletal pain. No cases of osteonecrosis of the jaw were reported, and no adverse effects on the healing of fractures were noted. The rates of renal and cardiovascular adverse events, including atrial fibrillation and stroke, were similar in the two groups. CONCLUSIONS: An annual infusion of zoledronic acid within 90 days after repair of a low-trauma hip fracture was associated with a reduction in the rate of new clinical fractures and with improved survival. (ClinicalTrials.gov number, NCT00046254 [ClinicalTrials.gov].).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“There are abundant data that patients with spine and hip fractures will have reduced fracture risk if treated with pharmacologic therapy.”
From Clinician’s Guide to Prevention and Treatment of Osteoporosis (2014) · cites this paper as [58]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This is true for fracture patients with BMD in both the low bone mass and osteoporosis range [49–58].”
From Clinician’s Guide to Prevention and Treatment of Osteoporosis (2014) · cites this paper as [58]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Zoledronic acid is also indicated for the prevention of new clinical fractures in patients (both women and men) who have recently had a low-trauma (osteoporosis-related) hip fracture [58].”
From Clinician’s Guide to Prevention and Treatment of Osteoporosis (2014) · cites this paper as [58]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Regression Models and Life-Tables
Cox, D. R. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_37 · Cited by 26,297
Holick, M. F. (2007) · New England Journal of Medicine · doi:10.1056/nejmra070553 · Cited by 13,720
Vertebral fracture assessment using a semiquantitative technique
Genant, H. K., Wu, C. Y., van Kuijk, C., & Nevitt, M. C. (1993) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650080915 · Cited by 3,691
A Multiple Testing Procedure for Clinical Trials
O'Brien, P. C., & Fleming, T. R. (1979) · Biometrics · doi:10.2307/2530245 · Cited by 3,311
Hip fractures in the elderly: A world-wide projection
Cooper, C. C., Campion, G., & Melton, L. J. (1992) · Osteoporosis International · doi:10.1007/bf01623184 · Cited by 3,225
Once-Yearly Zoledronic Acid for Treatment of Postmenopausal Osteoporosis
Black, D. M., Delmas, P. D., Eastell, R., Reid, I. R., Boonen, S., Cauley, J. A., Cosman, F., Lakatos, P., Leung, P. C., Man, Z., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa067312 · Cited by 2,986
Self-citationEffect of Risedronate on the Risk of Hip Fracture in Elderly Women
McClung, M. R., Geusens, P., Miller, P. D., Zippel, H., Bensen, W. G., Roux, C., Adami, S., Fogelman, I., Diamond, T., Eastell, R., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200102013440503 · Cited by 1,918
The Medical Dictionary for Regulatory Activities (MedDRA)
Brown, E. G., Wood, L., & Wood, S. (1999) · Drug Safety · doi:10.2165/00002018-199920020-00002 · Cited by 1,396
Ray, N. F., Chan, J. K., Thamer, M., & Melton, L. J. (1997) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.1997.12.1.24 · Cited by 1,281
Flagged first, then by citations
Research works printed but not linked: 2
- Davidson CW, 2001, N Z Med J, 114, 329
- 2003, World Health Organ Tech Rep Ser, 921, 1
Cited by
Sorted by citations
Items 801–900 of 1,000
Systemic effects of abnormal bone resorption on muscle, metabolism, and cognition
Trivedi, T., & Guise, T. A. (2021) · Bone · doi:10.1016/j.bone.2021.116245 · Cited by 20
Validation of a short questionnaire for estimating dietary calcium intakes
Macdonald, H. M., Garland, A., Burr, J. M., Strachan, A. A., Wood, A. D., Jamil, N. A., McLernon, D. J., & Black, A. J. (2014) · Osteoporosis International · doi:10.1007/s00198-014-2694-5 · Cited by 19
Access to Anti-osteoporosis Medication after Hip Fracture in Korean Elderly Patients
Yu, Y. M., Lee, J., & Lee, E. (2017) · Maturitas · doi:10.1016/j.maturitas.2017.06.021 · Cited by 19
Li, C., Hsu, J. C., Liang, F., Chang, Y., Chiu, C., & Wu, C. (2022) · Aging · doi:10.18632/aging.203927 · Cited by 18
Liu, K., Tan, G., Sun, W., Lü, Q., Tang, J., & Yu, D. (2022) · Archives of Orthopaedic and Trauma Surgery · doi:10.1007/s00402-022-04557-4 · Cited by 18
Briot, K., Cortet, B., Thomas, T., Audran, M., Blain, H., Breuil, V., Chapuis, L., Chapurlat, R. D., Fardellone, P., Féron, J.-M., et al. (2012) · Revue du Rhumatisme · doi:10.1016/j.rhum.2012.02.006 · Cited by 18
Lewiecki, M. E. (2009) · Core evidence · doi:10.2147/ce.s6011 · Cited by 18
Randomized Trial of Adjuvant Zoledronic Acid in Postmenopausal Women With High-Risk Breast Cancer
Leal, T., Tevaarwerk, A. J., Love, R. R., Stewart, J. A., Binkley, N., Eickhoff, J. C., Parrot, B., & Mulkerin, D. L. (2010) · Clinical Breast Cancer · doi:10.3816/cbc.2010.n.062 · Cited by 18
Sebastián Muñoz, G., Jorge Lavanderos, F., Loreto Vilches, A., Miguel Delgado, M., Karina Cárcamo, H., Stephania Passalaqua, H., & Mauricio Guarda, M. (2008) · Cuadernos de Cirugía · doi:10.4206/cuad.cir.2008.v22n1-11 · Cited by 18
Schulman, R. C., Moshier, E. L., Rho, L., Casey, M. F., Godbold, J., Zaidi, M., & Mechanick, J. I. (2016) · Endocrine Practice · doi:10.4158/ep151050.or · Cited by 18
Doria, C. (2016) · Clinical cases in mineral and bone metabolism · doi:10.11138/ccmbm/2016.13.3.195 · Cited by 18
Update on osteoporosis treatment
Nogués, X., & Martínez-Laguna, D. (2018) · Medicina Clínica (English Edition) · doi:10.1016/j.medcle.2018.03.011 · Cited by 18
Johnston, C. B., Holleran, A., Ong, T. D., McVeigh, U., & Ames, E. (2018) · Journal of Palliative Medicine · doi:10.1089/jpm.2018.0029 · Cited by 18
Gupta, M., Shah, S., Peterson, S. J., & Baim, S. (2018) · Osteoporosis International · doi:10.1007/s00198-018-4559-9 · Cited by 18
Bisphosphonate use in the horse: what is good and what is not?
Mitchell, A. A., Watts, A. E., Ebetino, F. H., & Suva, L. J. (2019) · BMC Veterinary Research · doi:10.1186/s12917-019-1966-x · Cited by 18
Secondary Fracture Prevention: Consensus Clinical Recommendations from a Multistakeholder Coalition
Conley, R. B., Adib, G., Adler, R. A., Åkesson, K., Alexander, I. M., Amenta, K. C., Blank, R. D., Brox, W. T., Carmody, E. E., Chapman‐Novakofski, K., et al. (2020) · Journal of Orthopaedic Trauma · doi:10.1097/bot.0000000000001743 · Cited by 19
Update on Rare Adverse Events from Osteoporosis Therapy and Bisphosphonate Drug Holidays
Adler, R. A. (2021) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2021.03.003 · Cited by 18
Li, Y., Tung, K., Cho, Y.-C., Lin, S., Lee, C.-H., & Chen, C. (2022) · BMC Geriatrics · doi:10.1186/s12877-022-03014-6 · Cited by 18
Bisphosphonate-Associated Osteomyelitis of the Jaw: Guidelines for Practicing Clinicians
Wimalawansa, S. J. (2008) · Endocrine Practice · doi:10.4158/ep.14.9.1150 · Cited by 18
Schwarz, P., Jørgensen, N. R., Mosekilde, L., & Vestergaard, P. (2011) · Journal of Osteoporosis · doi:10.4061/2011/259818 · Cited by 18
Osteopenia: A Diagnostic and Therapeutic Challenge
Lems, W. F., Raterman, H. G., van den Bergh, J. P., Bijlsma, H. W. J., Valk, N. K., Zillikens, M. C., & Geusens, P. (2011) · Current Osteoporosis Reports · doi:10.1007/s11914-011-0062-3 · Cited by 18
Pharmacokinetics, pharmacodynamics, and safety of zoledronic acid in horses
Nieto, J. E., Maher, O., Stanley, S. D., Knych, H. K. D., & Snyder, J. R. (2013) · American Journal of Veterinary Research · doi:10.2460/ajvr.74.4.550 · Cited by 18
Bisphosphonate treatment and fracture repair
McDonald, M. M., Schindeler, A., & Little, D. G. (2007) · BoneKEy-Osteovision · doi:10.1138/20070271 · Cited by 18
Oral bisphosphonates and risk of ischemic stroke: a case–control study
Christensen, S., Mehnert, F., Chapurlat, R. D., Baron, J. A., & Sørensen, H. T. (2010) · Osteoporosis International · doi:10.1007/s00198-010-1395-y · Cited by 18
Zoledronic acid for prevention and treatment of osteoporosis
Recknor, C. P. (2011) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2011.562201 · Cited by 18
Self-citationOtani, K., Teshima, T., Ito, Y., Kawaguchi, Y., Konishi, K., Takahashi, H., Ohigashi, H., Oshima, K., Araki, N., Nishiyama, K., et al. (2016) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2016.01.006 · Cited by 18
Efficacy of zoledronic acid in treatment of osteoporosis in men and women-a meta-analysis.
Liu, M., Guo, L., Pei, Y., Li, N., Jin, M., Ma, L., Liu, Y., Sun, B., & Li, C. (2015) · Europe PMC (PubMed Central) · Cited by 18
Goodwin, J. S., Zhou, J., Kuo, Y., & Baillargeon, J. (2016) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2016.09.015 · Cited by 18
Zhang, L., Shen, J., Yu, S., Huang, Q., & Xie, Z. (2014) · The Scientific World JOURNAL · doi:10.1155/2014/512512 · Cited by 18
Oral bisphosphonates and atrial fibrillation
Majumdar, S. R. (2008) · BMJ · doi:10.1136/bmj.39513.481065.80 · Cited by 18
Zoledronic Acid and Secondary Prevention of Fractures
Calis, K. A., & Pucino, F. (2007) · New England Journal of Medicine · doi:10.1056/nejme078192 · Cited by 18
Bonnick, S. L. (2011) · Journal of Clinical Densitometry · doi:10.1016/j.jocd.2011.07.006 · Cited by 18
Park, J. H., Kong, S. H., Lee, J., Oh, J., Lee, J.-R., Lee, H., & Kim, J. (2025) · Nature Communications · doi:10.1038/s41467-025-59718-x · Cited by 17
Successful Conservative Treatment
Kim, H., Jung, H. Y., Kim, M.-O., Joa, K., Kim, Y. J., Kwon, S.-Y., & Kim, C.-H. (2015) · Medicine · doi:10.1097/md.0000000000000446 · Cited by 17
Atmaca, A. A., Demirci, İ., Haymana, C., Taşçı, İ., Sahin, I., Çakal, E., Ata, N., Dağdelen, S., Salman, S. A., Emral, R., et al. (2021) · Osteoporosis International · doi:10.1007/s00198-021-06067-2 · Cited by 17
Corrao, G., Biffi, A., Porcu, G., Ronco, R., Adami, G., Alvaro, R., Bogini, R., Caputi, A. P., Cianferotti, L., Frediani, B., et al. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1137671 · Cited by 18
Henriksen, B. T., Krogseth, M., Andersen, R. D., Davies, M. N., Nguyen, C. T., Mathiesen, L., & Andersson, Y. (2023) · Journal of Orthopaedic Surgery and Research · doi:10.1186/s13018-023-03906-2 · Cited by 17
Zoledronic acid for hip fracture during initial hospitalization
Fan, W., Sun, X., Leder, B. Z., Lee, H., Ly, T. V., Pu, C. T., Franco‐Garcia, E., & Bolster, M. B. (2024) · Journal of Bone and Mineral Research · doi:10.1093/jbmr/zjae101 · Cited by 17
Harvey, L. A., Taylor, M. E., Harris, I. A., Mitchell, R. J., Cameron, I. D., Sarrami, P., & Close, J. (2024) · The Medical Journal of Australia · doi:10.5694/mja2.52470 · Cited by 17
Pharmacologic undertreatment of osteoporosis in Austrian nursing homes and senior's residences
Pietschmann, P., Azizi-Semrad, U., Pils, K., Fahrleitner‐Pammer, A., Resch, H., & Dobnig, H. (2010) · Wiener klinische Wochenschrift · doi:10.1007/s00508-010-1428-8 · Cited by 17
Klaus, J., Haenle, M. M., Schröter, C., Adler, G., von Boyen, G. B. T., Reinshagen, M., & von Tirpitz, C. (2011) · The American Journal of Gastroenterology · doi:10.1038/ajg.2011.59 · Cited by 17
Un modelo de deprescripción prudente
Hortal-Carmona, J., Cruz, I. A., & Ruiz, F. P. (2014) · Medicina Clínica · doi:10.1016/j.medcli.2014.02.026 · Cited by 17
Pharmacotherapy of Paget's disease of bone
Reid, I. R. (2012) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2012.662486 · Cited by 17
Adverse effects of bisphosphonates
Arboleya, L. R., Alpéri, M., & Alonso, S. (2011) · Reumatología Clínica (English Edition) · doi:10.1016/s2173-5743(11)70039-9 · Cited by 17
Huang, S., Lin, H. V., Zhu, X.-F., Chen, X., Fan, L., & Liu, C. (2014) · Endokrynologia Polska · doi:10.5603/ep.2014.0014 · Cited by 17
Gonnelli, S., Caffarelli, C., Iolascon, G., Bertoldo, F., Mauro, G. L., Patti, A., & Nuti, R. (2016) · Aging Clinical and Experimental Research · doi:10.1007/s40520-016-0681-8 · Cited by 17
Post-fracture care gap: a retrospective population-based analysis of Hong Kong from 2009 to 2012
Cheung, M., Ho, A. W., & Wong, S. (2018) · Hong Kong Medical Journal · doi:10.12809/hkmj187227 · Cited by 17
Recommandations françaises de la prise en charge et du traitement de l’ostéoporose masculine
Bouvard, B., Briot, K., Legrand, É., Blain, H., Breuil, V., Chapurlat, R. D., Duquenne, M., Guggenbuhl, P., Lespessailles, É., Thomas, T., et al. (2021) · Revue du Rhumatisme · doi:10.1016/j.rhum.2021.02.024 · Cited by 18
Summary of the draft federal clinical guidelines for osteoporosis
Belaya, Z. E., Rozhinskaya, L. Y., Grebennikova, T. A., Kanis, J. А., Pigarova, E. A., Rodionova, S. S., Toroptsova, N. V., Nikitinskaya, O. A., Skripnikova, I. A., Drapkina, O. M., et al. (2021) · Osteoporosis and Bone Diseases · doi:10.14341/osteo12710 · Cited by 17
Zoledronate Extends Health Span and Survival via the Mevalonate Pathway in a FOXO-dependent Manner
Chen, Z., Cordero, J. B., Alqarni, A. M., Slack, C., Zeidler, M. P., & Bellantuono, I. (2021) · The Journals of Gerontology Series A · doi:10.1093/gerona/glab172 · Cited by 17
Schini, M., Peel, N. F. A., Toronjo‐Urquiza, L., Thomas, E., Salam, S., Khwaja, A., Eastell, R., & Walsh, J. (2021) · Osteoporosis International · doi:10.1007/s00198-021-06160-6 · Cited by 17
Baleanu, F., Moreau, M., Charles, A., Iconaru, L., Karmali, R., Surquin, M., Benoit, F., Mugisha, A., Paesmans, M., Rubinstein, M., et al. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac092 · Cited by 17
Lau, A. N., Ioannidis, G., Potts, Y., Giangregorio, L., van der Horst, M., Adachi, J. D., & Παπαϊωάννου, Α. (2010) · BMC Geriatrics · doi:10.1186/1471-2318-10-73 · Cited by 17
Self-citationEfectos adversos de los bisfosfonatos
Arboleya, L. R., Alpéri, M., & Alonso, S. (2011) · Reumatología Clínica · doi:10.1016/j.reuma.2010.10.005 · Cited by 18
Kang, H., Chen, Y., Han, G., Huang, H., Chen, W., Wang, X., Zhu, Y., & Xiao, S. (2016) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph13020157 · Cited by 18
Models of Secondary Fracture Prevention
Ganda, K., Mitchell, P., & Seibel, M. J. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-813136-7.00003-x · Cited by 17
Management of difficult osteoporosis
Russell, L. (2018) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2019.04.002 · Cited by 17
Pathobiology of Cancer Regimen-Related Toxicities
Sonis, S. T., & Keefe, D. M. K. (2013) · Springer eBooks · doi:10.1007/978-1-4614-5438-0 · Cited by 17
Evaluation of a program of integrated care to reduce recurrent osteoporotic fractures
Goltz, L., Degenhardt, G. A., Maywald, U., Kirch, W., & Schindler, C. (2013) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.3399 · Cited by 17
Management of osteoporosis in the aging male: Focus on zoledronic acid
Piper, P. K. (2009) · Clinical Interventions in Aging · doi:10.2147/cia.s4295 · Cited by 17
Bisphosphonates and metabolic bone disease in the ICU
Hollander, J. M., & Mechanick, J. I. (2009) · Current Opinion in Clinical Nutrition & Metabolic Care · doi:10.1097/mco.0b013e328321cda6 · Cited by 17
Denosumab – an emerging treatment for postmenopausal osteoporosis
Lewiecki, E. M. (2010) · Expert Opinion on Biological Therapy · doi:10.1517/14712591003604708 · Cited by 18
Clinical Update on Nursing Home Medicine: 2008
Messinger‐Rapport, B. J., Thomas, D. R., Gammack, J. K., & Morley, J. E. (2008) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2008.07.006 · Cited by 17
Einsatz der Bisphosphonate in der Orthopädie und Unfallchirurgie
Bartl, R., Bärtl, C., & Gradinger, R. (2008) · Der Orthopäde · doi:10.1007/s00132-008-1280-y · Cited by 17
Crosstalk between kidney and bones: New perspective for modulating osteoporosis
Duan, Y., Zhao, L., Lu, Y., Li, J., & Li, S. (2025) · Ageing Research Reviews · doi:10.1016/j.arr.2025.102776 · Cited by 16
Healthspan versus lifespan: new medicines to close the gap
Crane, P. A., WILKINSON, G. F., & Teare, H. (2022) · Nature Aging · doi:10.1038/s43587-022-00318-5 · Cited by 19
‘Skeletal Age’ for mapping the impact of fracture on mortality
Tran, T. S., Ho-Le, T. P., Bliuc, D., Abrahamsen, B., Hansen, L., Vestergaard, P., & Nguyen, T. V. (2023) · eLife · doi:10.7554/elife.83888 · Cited by 16
Liu, S., Tan, Y., Huang, W., Luo, H., Pan, B., & Wu, S. (2023) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2023.152304 · Cited by 17
Bisphosphonates and glucocorticoid-induced osteoporosis: Efficacy and tolerability
Lespessailles, É. (2012) · Joint Bone Spine · doi:10.1016/j.jbspin.2012.08.005 · Cited by 16
Zhang, H., Huang, Q., Gu, J., Hu, W., Liu, Y., Hu, Y.-Q., & Zhang, Z. (2012) · Acta Pharmacologica Sinica · doi:10.1038/aps.2011.172 · Cited by 16
Herrero, S., & Picó, Y. (2016) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2016.02.053 · Cited by 16
Ferrières, L., Degboé, Y., Laroche, M., Constantin, A., & Ruyssen‐Witrand, A. (2020) · Archives of Osteoporosis · doi:10.1007/s11657-019-0672-4 · Cited by 16
Bisphosphonate drug holidays: Risk of fractures and mortality in a prospective cohort study
Pfeilschifter, J., Steinebach, I., Trampisch, H. J., & Rudolf, H. (2020) · Bone · doi:10.1016/j.bone.2020.115431 · Cited by 16
Mattheos, N., Caldwel, P., Petcu, E. B., Ivanovski, S., & Reher, P. (2013) · PubMed · Cited by 16
Weycker, D. A., Lamerato, L. E., Schooley, S., Macarios, D., Woodworth, T., Yurgin, N., & Oster, G. (2012) · Osteoporosis International · doi:10.1007/s00198-012-2108-5 · Cited by 16
Wnt therapy for bone loss: golden goose or Trojan horse?
Enders, G. H. (2009) · Journal of Clinical Investigation · doi:10.1172/jci38973 · Cited by 16
Osteoporosis and Upper Extremity Fragility Fractures
Foote, J. E., & Rozental, T. D. (2011) · The Journal Of Hand Surgery · doi:10.1016/j.jhsa.2011.09.025 · Cited by 16
Osteoporosis senil: una actualización
Alonso‐Bouzón, C., & Duque, G. (2011) · Revista Española de Geriatría y Gerontología · doi:10.1016/j.regg.2011.02.010 · Cited by 16
Bisphosphonate-induced Severe Hypocalcemia - A Case Report -
Do, W.-S., Park, J.-K., Park, M.-I., Kim, H.-S., Kim, S., & Lee, D.-H. (2012) · Journal of Bone Metabolism · doi:10.11005/jbm.2012.19.2.139 · Cited by 16
Patterns of treatment in Australian men following fracture
Otmar, R., Henry, M. J., Kotowicz, M. A., Nicholson, G. C., Korn, S., & Pasco, J. A. (2010) · Osteoporosis International · doi:10.1007/s00198-010-1204-7 · Cited by 16
Undertreatment of Osteoporosis Following Hip Fractures in Jeju Cohort Study
Kim, S. R., Park, Y., Kang, S. Y., Nam, K. W., Park, Y. G., & Ha, Y. (2014) · Journal of Bone Metabolism · doi:10.11005/jbm.2014.21.4.263 · Cited by 16
Yamazaki, T., Takahashi, K., & Bessho, K. (2014) · Reviews on Recent Clinical Trials · doi:10.2174/1574887109666140423120614 · Cited by 16
Dimai, H. P., Pietschmann, P., Resch, H., Preisinger, E., Fahrleitner‐Pammer, A., Dobnig, H., & Klaushofer, K. (2009) · Wiener Medizinische Wochenschrift · doi:10.1007/s10354-009-0656-x · Cited by 16
Lee, R. E., Jr., Pearson, M., Lyles, K. W., Jenkins, P. M., & Colon-Emeric, C. S. (2016) · Rural and Remote Health · doi:10.22605/rrh3440 · Cited by 16
Self-citationSpechbach, H., Fabreguet, I., Saule, E., Hars, M., Stirnemann, J., Ferrari, S., Rizzoli, R., & Chevalley, T. (2019) · Osteoporosis International · doi:10.1007/s00198-019-04900-3 · Cited by 16
An Observational Study on the Adherence to Treatment Guidelines of Osteopenia
Buencamino, M. C. A., Sikon, A. L., Jain, A., & Thacker, H. L. (2009) · Journal of Women s Health · doi:10.1089/jwh.2008.0897 · Cited by 16
Clinical assessment of fracture risk and novel therapeutic strategies to combat osteoporosis
Nanes, M. S., & Kallen, C. B. (2009) · Fertility and Sterility · doi:10.1016/j.fertnstert.2009.05.049 · Cited by 16
Vincent, G., Adachi, J. D., Schemitsch, E. H., Tarride, J., Ho, N., Wani, R. J., & Brown, J. P. (2024) · JBMR Plus · doi:10.1093/jbmrpl/ziae002 · Cited by 15
Self-citationSchini, M., Vilaça, T., Vittinghoff, E., Lui, L., Ewing, S. K., Thompson, A. R., Bauer, D. C., Bouxsein, M., Black, D. M., & Eastell, R. (2024) · Journal of Bone and Mineral Research · doi:10.1093/jbmr/zjae040 · Cited by 15
The Orthopaedic Implications of Diphosphonate Therapy
Weaver, M. J., Miller, M. A., & Vrahas, M. S. (2010) · Journal of the American Academy of Orthopaedic Surgeons · doi:10.5435/00124635-201006000-00009 · Cited by 15
Brouwers, J. E. M., van Rietbergen, B., & Bouxsein, M. (2008) · Calcified Tissue International · doi:10.1007/s00223-008-9160-3 · Cited by 15
Update on Equine Odontoclastic Tooth Resorption and Hypercementosis
Limone, L. E. (2020) · Veterinary Clinics of North America Equine Practice · doi:10.1016/j.cveq.2020.08.006 · Cited by 15
Wu, S., Chen, J., & Tsai, C.-J. (2020) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2020.12.014 · Cited by 15
Jalan, H., Perumal, R., Prabhu, S., Palanivelayutham, S. S., Viswanathan, V. K., & Rajasekaran, S. (2021) · Journal of Clinical Orthopaedics and Trauma · doi:10.1016/j.jcot.2021.06.002 · Cited by 15
Liu, J., Gong, T., Xu, X., Fox, K. M., Oates, M. K., & Gandra, S. (2021) · Osteoporosis International · doi:10.1007/s00198-021-06084-1 · Cited by 15
Makras, P., Petrikkos, P., Anastasilakis, A. D., Kolynou, A., Katsarou, A., Tsachouridou, Ο., Metallidis, S., & Yavropoulou, M. P. (2021) · Bone Reports · doi:10.1016/j.bonr.2021.101128 · Cited by 15
High Rates of Imminent Subsequent Fracture After Femoral Neck Fracture in the Elderly
Bogoch, E. R., Marcano-Fernández, F. A., Schemitsch, E. H., Zhou, Q. X., Bzovsky, S., Bhandari, M., Schneider, P., Swiontkowski, M. F., Sprague, S., the FAITH Investigators, et al. (2022) · Journal of Bone and Joint Surgery · doi:10.2106/jbjs.22.00088 · Cited by 15
Current options for the treatment of Paget’s disease of the bone
Merlotti, D., Gennari, L., Martini, C., & Nuti (2009) · Open Access Rheumatology Research and Reviews · doi:10.2147/oarrr.s4504 · Cited by 15
Pattern and cause of fractures in patients who abuse alcohol: what should we do about it?
Kelly, K. N., & Kelly, C. A. (2013) · Postgraduate Medical Journal · doi:10.1136/postgradmedj-2013-131990 · Cited by 15
Osteoporosis Treatment Following Hip Fracture: How Rates Vary by Service
Gregory, P. C., Lam, D., & Howell, P. (2010) · Southern Medical Journal · doi:10.1097/smj.0b013e3181ebe96c · Cited by 15
Metadata
- Authors
- Lyles, K. W., Colón-Emeric, C. S., Magaziner, J. S., Adachi, J. D., Pieper, C. F., Mautalen, C., Hyldstrup, L., Recknor, C., Nordsletten, L., Moore, K. A., Lavecchia, C., Zhang, J., Mesenbrink, P., Hodgson, P. K., Abrams, K., Orloff, J. J., Horowitz, Z., Eriksen, E. F., & Boonen, S.
- Affiliations
- Veterans Health Administration (US)
- University of Maryland, Baltimore (US)
- McMaster University (CA)
- Duke Medical Center (US)
- Hvidovre Hospital (DK)
- Oslo University Hospital (NO)
- Savient Pharmaceuticals (United States) (US)
- Novartis (Switzerland) (CH)
- KU Leuven (BE)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2007-11
- Volume
- 357
- Issue
- 18
- Pages
- 1799-1809
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC2324066
- OpenAlex
- W2163830908
- Cited by
- 2,003
- References
- 35
- Citations by year
- 2026: 53 · 2025: 88 · 2024: 67 · 2023: 75 · 2022: 78 · 2021: 119 · 2020: 104 · 2019: 94 · 2018: 92 · 2017: 79 · 2016: 97 · 2015: 92 · 2014: 106 · 2013: 115 · 2012: 122
- FWCI
- 160.83
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion)
- PubMed Central (acceptedVersion)
- IRIS (submittedVersion)
- SERVAL (Université de Lausanne) (submittedVersion)
- Funders
- Amgen
- Eli Lilly and Company
- Pfizer
- GlaxoSmithKline
- Sanofi
- Savient Pharmaceuticals
- Novo Nordisk
- Servier
- National Institute on Aging (K23AG024787)
- Topics
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Health Sciences › Medicine › Surgery › Hip and Femur Fractures
- Keywords
- zoledronic acid, hip fracture, bisphosphonates, fracture prevention, vertebral fractures, non-vertebral fractures, mortality, postoperative treatment, osteoporosis, adverse events, osteonecrosis of the jaw
- MeSH terms
- Zoledronic Acid, Aged, Aged, 80 and over, Calcium, Diphosphonates, Double-Blind Method, Drug Administration Schedule, Drug Therapy, Combination, Female, Hip Fractures, Humans, Imidazoles, Infusions, Intravenous, Male, Middle Aged, Vitamin D, Bone Density, Survival Analysis, Bone Density Conservation Agents, Fractures, Bone
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
